The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Emerging insights into Transforming growth factor Smad signal in hepatic fibrogenesis
Open accessAbstract
rrespective of initial stimuli, increased production of type I collagen is a common hallmark of fibrotic diseases in various organs including the liver.A dynamic balance between the production and degradation of collagen is seen, which is rigorously controlled by several growth factors and cytokines.Of these, transforming growth factor b (TGFb) is the most potent factor in stimulating type I collagen gene transcription.It also regulates expression of matrix metalloproteinases and their inhibitors, and modulates inflammatory reactions by influencing T cell functions.Therefore, TGFb is considered to be the major factor accelerating liver fibrosis.Identification and characterisation of Smad proteins, intracellular mediators of the signal transduction of TGFb, have led to a better understanding of the precise mechanisms of TGFb functions from the viewpoint of its intracellular signalling pathway and crosstalk with other factors.Several studies have focused on the suppression of TGFb activation and intervention of the TGFb/Smad signalling pathways to treat liver fibrosis.However, as generalised blockade of TGFb activity may result in the promotion of carcinogenesis and excessive immune reactions, much attention has to be paid to selective intervention of the TGFb/ Smad signal specifically in collagen-producing cells in the fibrotic tissue.TGFb also affects the growth and differentiation of stem and progenitor cells.From this point of view, a new concept of the treatment for liver fibrosis may arise from the discipline of stem cell biology by modulating TGFb and Smad signalling in stem/progenitor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J., Seoane, J., & Wotton, D. (2005) · Genes & Development · doi:10.1101/gad.1350705 · Cited by 2,452
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,809
Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,634
Zeisberg, M., Hanai, J.-I., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., & Kalluri, R. (2003) · Nature Medicine · doi:10.1038/nm888 · Cited by 1,346
A mechanism of repression of TGFbeta / Smad signaling by oncogenic Ras
Kretzschmar, M., Doody, J., Timokhina, I., & Massague, J. (1999) · Genes & Development · doi:10.1101/gad.13.7.804 · Cited by 1,004
Yang, X. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1280 · Cited by 889
Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1
Kretzschmar, M., Doody, J., & Massagu, J. (1997) · Nature · doi:10.1038/39348 · Cited by 877
Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., & Miyazono, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100008200 · Cited by 844
Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway
Ulloa, L., Doody, J., & Massagué, J. (1999) · Nature · doi:10.1038/17826 · Cited by 812
Gressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Moreover, SMAD6 and SMAD7, which negatively regulate TGF-β signaling, are considered as anti-fibrotic factors [139,140].”
BackgroundMechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update
Elpek, G. Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7260 · Cited by 382
Non-invasive diagnosis of liver fibrosis and cirrhosis
Lurie, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11567 · Cited by 352
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Karsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A.-C., Smith, V., Adamkewicz, J. I., Christiansen, C., & Leeming, D. J. (2013) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2012.474 · Cited by 279
Cellular and molecular mechanisms of intestinal fibrosis
Speca, S. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i28.3635 · Cited by 272
Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Gressner, O. A., & Gressner, A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01826.x · Cited by 270
Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236
Fabre, T., Kared, H., Friedman, S. L., & Shoukry, N. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400861 · Cited by 150
Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses
Alonso-Merino, E., Martín Orozco, R., Ruíz-Llorente, L., Martínez-Iglesias, O. A., Velasco-Martín, J. P., Montero-Pedrazuela, A., Fanjul-Rodríguez, L., Contreras-Jurado, C., Regadera, J., & Aranda, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506113113 · Cited by 108
The role of vitamin D and vitamin D binding protein in chronic liver diseases
Pop, T. L., Sîrbe, C., Benţa, G., Mititelu, A., & Grama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810705 · Cited by 105
Vitamin D and liver fibrosis: molecular mechanisms and clinical studies
Udomsinprasert, W., & Jittikoon, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.140 · Cited by 99
Bansal, R., Nakagawa, S., Yazdani, S., van Baarlen, J., Venkatesh, A., Koh, A. P., Song, W.-M., Goossens, N., Watanabe, H., Beasley, M. B., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.213 · Cited by 96
Said, M. M., Azab, S. S., Saeed, N. M., & El-Demerdash, E. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0010.8662 · Cited by 65
Zhong, L., Zhao, J., Huang, L., Liu, Y., Pang, X., Zhan, K., Li, S., Xue, Q., Pan, X., & Deng, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1316 · Cited by 43
Lu, N., Liu, Y., Tang, A., Chen, L., Miao, D., & Yuan, X. (2015) · BioMed Research International · doi:10.1155/2015/794862 · Cited by 21
Metadata
- Authors
- Inagaki, Y., & Okazaki, I.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2007-02-01
- Volume
- 56
- Issue
- 2
- Pages
- 284-292
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2017961355
- Cited by
- 464
- References
- 89
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.